Weight-loss drugs are the next startup platform shift
Author
Publisher
Date Published

The year’s top venture capital story has been The Next Great Platform Shift, as every tech startup is either incorporating, or trying not to get run over by, artificial intelligence.

But, but, but There’s also been a second sea change building in 2023: The rise of GLP-1 weight loss drugs, like Ozempic and Wegovy, which could revolutionize a health care sector that receives around one-quarter of all VC dollars.

The big picture: This isn’t so much about the anti-obesity drugmakers themselves, although there obviously will be some winners there beyond Novo Nordisk.

Zoom out: It may be useful to look at AI as a comp.

The bottom line: “The two biggest trends in the last year are three-letter acronyms: LLM and GLP,” says Bijan Salehizadeh, co-founder of venture firm NaviMed Capital, who adds that he believes the upward line from anti-obesity drugs will be straighter than it will be for AI.